1University of Michigan and Veterans Affairs Medical Center, Ann Arbor 48105, USA. eyoung@umich.edu
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Erythropoietin treatment improves outcomes for dialysis patients with end-stage renal disease (ESRD). Optimal response depends on dialysis dose and dialyzer type, with synthetic membranes potentially enhancing erythropoietin effectiveness.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: